



Immuron Improves its Royalty Payment Terms under its Technology Agreement with Hadasit

Melbourne, Australia - 2 September 2014: Australian biopharmaceutical company Immuron Limited (ASX: IMC) is pleased to announce an amended agreement for reduced royalty payment obligations to Hadasit Medical Research Services & Development Limited. Hadasit is the technology transfer company of the Hadassah Medical Organization in Jerusalem Israel and Immurons' principal research and development collaborator.

The royalties have been amended so that they are now derived from net income received by Immuron rather than from revenues received by a licensee of Immuron. This provides further certainty in the commercialization of Immuron's NASH product and any other prescription product developed with the intellectual property assigned by Hadasit to Immuron.

Immuron also reduced the royalty payable on all its over-the-counter products.

Amos Meltzer, Immuron's Chief Executive Officer said: "The license agreement was renegotiated to reflect the significant investment Immuron and its shareholders are making in the upcoming Phase II trial and we have been able to attain a result that gives the company and its shareholders a more robust financial structure and a stronger business model.

Hadasit has been a strong partner over the past five years and continues to be so. We look forward to continuing our successful collaboration with Hadasit and Hadassah."

Contacts:

Amos Meltzer
Chief Executive Officer
+61 (0)437 587 680

Amanda Loh
Investor Relations, Buchan Consulting
+61 (0)3 9866 4722

Websites: www.immuron.com and www.travelan.com

About Immuron

Immuron is a biopharmaceutical company focused on oral immunotherapy treatments using dairy-derived antibody products for humans. Immuron's technology platform products all have a very high safety profile. The company's current products and product candidates address infectious diseases of the gastrointestinal tract as well as chronic diseases. Immuron has an on-market product, Travelan®, for preventing travellers' diarrhoea. Immuron also has a phase 2 clinical product candidate for the treatment of inflamed fatty liver disease, known as Non-Alcoholic Steatohepatitis or NASH. Immuron's main scientific alliances are with Hadassah Medical Center (Israel) and Monash University (Australia).